<DOC>
	<DOCNO>NCT03096990</DOCNO>
	<brief_summary>The study include representative sample 150 patient active Psoriatic Arthritis ( PsA ) treat rheumatologist decide begin treatment apremilast . This study non-interventional , drug dose treatment duration sole discretion treat rheumatologist , accordance local label daily clinical practice . APOLO national ( Belgium ) , multicentre , prospective , non-interventional , post-marketing study .</brief_summary>
	<brief_title>A Study Real-life Management Psoriatic Arthritis Patients Treated With Otezla® ( Apremilast ) Belgium</brief_title>
	<detailed_description>Patient care follow routine clinical practice , involve regular follow-up visit , without mandatory visit . In daily practice , patient usually see treat rheumatologist every 3 month . In study , patient followed-up least 6 month 18 month apremilast treatment initiation . Considering Belgian National Institute Health Disability Insurance ( NIHDI ) query address 31st January 2019 , patient data collect May/June 2018 . Assuming recruitment phase 12-month duration start December 2016 , individual patient follow-up time range 6 18 month , depend inclusion date . During study , expect collect data inclusion 6 month apremilast initiation patient . As per NIHDI recommendation , patient consult treat rheumatologist 6 month apremilast initiation order evaluate treatment response decide treatment continuation additional period 12 month . For patient recruit early study , data collect next follow-up visit 18 month apremilast initiation . Only data pertain visit occur 9 ( ± 1 ) , 12 ( ± 1 ) , 15 ( ±1 ) , 18 ( ± 1 ) month treatment initiation collect . If study visit occur approximately 3 ( ± 1 ) month treatment initiation , data also record . All clinical data collect non-interventional study routinely document patient 's medical record , main source information . The study data collect via electronic Case Report Form ( eCRF ) . Data source document include PRO-questionnaires enter eCRF investigator authorise appropriately design train study site personnel . Data enter eCRF review consistency Data Manager use automated logical check ( issue automatic query generate system ) manual review ( issue manual check set Data Manager Monitor eCRF ) . All data collect within eCRF approve electronically sign date Investigator designee . At conclusion study , final statistical analysis , eCRF study data lock addition correction . During study , Clinical Research Associate ( CRA ) contact study site regular basis order check progress conduct study . If issue regard study conduct arise , additional on-site visit may perform . In particular , quality analysis also perform base data quality , decide whether on-site monitoring necessary , site percentage patient . During monitor visit , eCRFs , patient 's source document , study documentation review CRA . Accuracy check perform source data verification direct comparison entry make onto eCRF appropriate source documentation . Adverse event AEs cod use Medical Dictionary Regulatory Activities ( MedDRA ) terminology . The detailed methodology statistical analysis document statistical analysis plan ( SAP ) . The SAP write Clinical Research Organisation ( CRO ) charge study validate sponsor prior perform analysis obligatory database lock . A scientific committee select study . This committee provide advice SAP .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Apremilast</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Patients meet ALL follow criterion enrol : Male female age least 18 year , With diagnosis active Psoriatic Arthritis ( PsA ) , For treat physician make decision commence apremilast treatment accordance local label reimbursement criterion ( refer reimbursement condition mention Section 1.2 ) , Able follow instruction study , Having sign Informed Consent Form ( ICF ) . Patients meet AT LEAST one follow exclusion criterion exclude : Women pregnant , breastfeed plan become pregnant , Nonmenopausal woman use adequate contraception method , Patients hypersensitivity apremilast one excipients .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Psoriatic Arthritis</keyword>
	<keyword>Observational</keyword>
	<keyword>Otezla</keyword>
	<keyword>Apremilast</keyword>
	<keyword>Real-Life management</keyword>
	<keyword>Belgium</keyword>
	<keyword>APOLO</keyword>
	<keyword>CC-10004</keyword>
</DOC>